Price
$0.653
Decreased by -5.16%
Dollar Volume
2.54 M
ADR%
22.17
Earnings Report Date (estimate)
Mar 29, 23 (-0.38)
Market Cap.
16.96 M
Shares Float
17.25 M
Shares Outstanding
25.97 M
Beta
1.20
Price / Earnings
-0.20
BPR
5.60
20D Range
0.57 1.45
50D Range
0.57 1.75
200D Range
0.57 2.77
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 21, 22 -0.47
Increased by +48.91%
-0.17
Decreased by -176.47%
Aug 16, 22 -0.45
Increased by +76.80%
-0.06
Decreased by -650.00%
May 16, 22 -0.44
Increased by +10.20%
-0.51
Increased by +13.73%
Apr 1, 22 -0.92
Decreased by -19.48%
-0.41
Decreased by -124.39%
Mar 31, 22 -0.92
Decreased by -55.93%
-0.41
Decreased by -124.39%
Nov 10, 21 -1.94
Decreased by -198.46%
-0.51
Decreased by -280.39%
Aug 12, 21 -0.49
Decreased by -4.26%
-0.63
Increased by +22.22%
May 11, 21 -0.77
Decreased by -5.48%
-0.62
Decreased by -24.19%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-8.24 M
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 292.00 K
Increased by +N/A%
-7.98 M
Decreased by N/A%
Decreased by -2.73 K%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-7.77 M
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 570.00 K
Increased by +N/A%
-10.23 M
Decreased by N/A%
Decreased by -1.79 K%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
0.00
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
0.00
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
0.00
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
0.00
Decreased by N/A%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.